{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T02:24:43Z","timestamp":1787279083764,"version":"build-2736575974"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":72,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100011033","name":"Thermo Fisher Scientific","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011033","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by multisystem inflammation, predominantly affecting women of reproductive age. Consequently, its impact on pregnancy outcomes represents a critical clinical concern. Advances in disease monitoring and management have reduced pregnancy-related complications; however, risks remain higher than in the general population. Adverse outcomes, including fetal loss, preterm delivery, preeclampsia, thrombotic events, and low birth weight, are particularly common in patients with lupus nephritis. Placental insufficiency and immune-mediated inflammatory mechanisms are thought to contribute to these complications. Pregnancy may also precipitate disease reactivation, although the timing and frequency of flares are variable. Higher disease activity is consistently associated with poorer outcomes, yet prediction of flares or adverse events remains challenging. In addition, certain SLE therapies pose teratogenic risks, underscoring the importance of individualized treatment planning. Optimal outcomes are most likely when conception occurs during a period of disease quiescence, with close multidisciplinary monitoring and the use of pregnancy-compatible therapies to maintain disease control.<\/jats:p>","DOI":"10.1186\/s42358-026-00555-x","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T16:24:40Z","timestamp":1781108680000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Systemic lupus erythematosus and pregnancy: a comprehensive clinical review of maternal, fetal, and treatment considerations"],"prefix":"10.1186","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6293-3429","authenticated-orcid":false,"given":"Diego F.","family":"Wyszynski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"issue":"9","key":"555_CR1","doi-asserted-by":"publisher","first-page":"103607","DOI":"10.1016\/j.autrev.2024.103607","volume":"23","author":"MG Danieli","year":"2024","unstructured":"Danieli MG, Antonelli E, Longhi E, Gangemi S, Allegra A. The role of microbiota and oxidative stress axis and the impact of intravenous immunoglobulin in systemic lupus erythematosus. Autoimmun Rev. 2024;23(9):103607.","journal-title":"Autoimmun Rev"},{"issue":"6","key":"555_CR2","doi-asserted-by":"publisher","first-page":"105713","DOI":"10.1016\/j.jbspin.2024.105713","volume":"91","author":"V Le Guern","year":"2024","unstructured":"Le Guern V, Guettrot-Imbert G, Dupr\u00e9 A, Perol S, Pannier E, Morel N, Costedoat-Chalumeau N. Issues with pregnancy in systemic lupus. Joint Bone Spine. 2024;91(6):105713.","journal-title":"Joint Bone Spine"},{"issue":"2","key":"555_CR3","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/1756-185X.12419","volume":"18","author":"A Aggarwal","year":"2015","unstructured":"Aggarwal A, Srivastava P. Childhood onset systemic lupus erythematosus: how is it different from adult SLE? Int J Rheum Dis. 2015;18(2):182\u201391.","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"555_CR4","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1093\/rheumatology\/ket330","volume":"53","author":"YM Chen","year":"2014","unstructured":"Chen YM, Lin CH, Chen HH, Chang SN, Hsieh TY, Hung WT, et al. Onset age affects mortality and renal outcome of female systemic lupus erythematosus patients: a nationwide population-based study in Taiwan. Rheumatology (Oxford). 2014;53(1):180\u20135.","journal-title":"Rheumatology (Oxford)"},{"key":"555_CR5","doi-asserted-by":"publisher","first-page":"941586","DOI":"10.3389\/fimmu.2022.941586","volume":"13","author":"AS Castellanos Gutierrez","year":"2022","unstructured":"Castellanos Gutierrez AS, Figueras F, Morales-Prieto DM, Schleu\u00dfner E, Espinosa G, Ba\u00f1os N. Placental damage in pregnancies with systemic lupus erythematosus: A narrative review. Front Immunol. 2022;13:941586.","journal-title":"Front Immunol"},{"issue":"6","key":"555_CR6","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1002\/art.37897","volume":"65","author":"M Al-Maini","year":"2013","unstructured":"Al-Maini M, Jeyalingam T, Brown P, Lee JJ, Li L, Su J, et al. A hot spot for systemic lupus erythematosus, but not for psoriatic arthritis, identified by spatial analysis suggests an interaction between ethnicity and place of residence. Arthritis Rheum. 2013;65(6):1579\u201385.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"555_CR7","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1093\/rheumatology\/kex260","volume":"56","author":"F Rees","year":"2017","unstructured":"Rees F, Doherty M, Grainge MJ, Lanyon P, Zhang W. The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology (Oxford). 2017;56(11):1945\u201361.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"555_CR8","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1191\/0961203306lu2305xx","volume":"15","author":"N Danchenko","year":"2006","unstructured":"Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus. 2006;15(5):308\u201318.","journal-title":"Lupus"},{"issue":"2","key":"555_CR9","doi-asserted-by":"publisher","first-page":"e244","DOI":"10.18295\/squmj.2021.21.02.013","volume":"21","author":"N Al-Riyami","year":"2021","unstructured":"Al-Riyami N, Salman B, Al-Rashdi A, Al-Dughaishi T, Al-Haddabi R, Hassan B. Pregnancy Outcomes in Systemic Lupus Erythematosus Women: A single tertiary centre experience. Sultan Qaboos Univ Med J. 2021;21(2):e244\u201352.","journal-title":"Sultan Qaboos Univ Med J"},{"issue":"2","key":"555_CR10","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/art.20864","volume":"52","author":"ME Clowse","year":"2005","unstructured":"Clowse ME, Magder LS, Witter F, Petri M. The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum. 2005;52(2):514\u201321.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"555_CR11","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1111\/aogs.14880","volume":"103","author":"K Rosta","year":"2024","unstructured":"Rosta K, Heinzl F, Kuczwara V, Schindler S, Falcone V, Catic A, et al. Pregnancy outcomes in patients with systemic lupus erythematosus compared to a high-risk tertiary cohort and to standard population from the Austrian birth registry. Acta Obstet Gynecol Scand. 2024;103(9):1820\u20138.","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"4","key":"555_CR12","doi-asserted-by":"publisher","first-page":"103744","DOI":"10.1016\/j.autrev.2025.103744","volume":"24","author":"J Cajamarca-Baron","year":"2025","unstructured":"Cajamarca-Baron J, Sanmiguel-Reyes C, Bedoya-Loaiza JE, Casta\u00f1eda-Gonzalez JP, Acelas-Gonzalez GE, Molina-Giraldo S, et al. Maternal and fetal outcomes in Latin American SLE pregnancies: A systematic review and meta-analysis. Autoimmun Rev. 2025;24(4):103744.","journal-title":"Autoimmun Rev"},{"issue":"3","key":"555_CR13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1055\/s-0044-1793827","volume":"42","author":"A Moyer","year":"2024","unstructured":"Moyer A, Edens C. Impact of Systemic Lupus Erythematosus on Conception: Insights into Infertility, Fertility Preservation, Assisted Reproductive Technology, and Pregnancy Outcomes. Semin Reprod Med. 2024;42(3):209\u201327.","journal-title":"Semin Reprod Med"},{"issue":"3","key":"555_CR14","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s10067-025-07341-y","volume":"44","author":"Y Yang","year":"2025","unstructured":"Yang Y, Zhou Y, Zhang X, Huang C, Liu L, Zhao J, et al. Risk and protective factors of disease flare during pregnancy in systemic lupus erythematosus: a systematic review and meta-analysis. Clin Rheumatol. 2025;44(3):887\u201399.","journal-title":"Clin Rheumatol"},{"issue":"4","key":"555_CR15","doi-asserted-by":"publisher","first-page":"99700","DOI":"10.5527\/wjn.v13.i4.99700","volume":"13","author":"T Elahi","year":"2024","unstructured":"Elahi T, Ahmed S, Mubarak M. Relationship of lupus nephritis and pregnancy: A narrative review. World J Nephrol. 2024;13(4):99700.","journal-title":"World J Nephrol"},{"issue":"1","key":"555_CR16","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/s12884-025-07471-w","volume":"25","author":"VR Murvai","year":"2025","unstructured":"Murvai VR, Gali\u0219 R, Panaitescu A, Radu CM, Ghitea TC, Trif P, et al. Antiphospholipid syndrome in pregnancy: a comprehensive literature review. BMC Pregnancy Childbirth. 2025;25(1):337.","journal-title":"BMC Pregnancy Childbirth"},{"issue":"2","key":"555_CR17","doi-asserted-by":"publisher","first-page":"e1271","DOI":"10.1016\/j.ajog.2008.03.012","volume":"199","author":"ME Clowse","year":"2008","unstructured":"Clowse ME, Jamison M, Myers E, James AH. A national study of the complications of lupus in pregnancy. Am J Obstet Gynecol. 2008;199(2):e1271\u20136.","journal-title":"Am J Obstet Gynecol"},{"issue":"2 Pt 1","key":"555_CR18","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/01.AOG.0000194205.95870.86","volume":"107","author":"ME Clowse","year":"2006","unstructured":"Clowse ME, Magder LS, Witter F, Petri M. Early risk factors for pregnancy loss in lupus. Obstet Gynecol. 2006;107(2 Pt 1):293\u20139.","journal-title":"Obstet Gynecol"},{"issue":"10","key":"555_CR19","first-page":"2127","volume":"30","author":"CA Clark","year":"2003","unstructured":"Clark CA, Spitzer KA, Nadler JN, Laskin CA. Preterm deliveries in women with systemic lupus erythematosus. J Rheumatol. 2003;30(10):2127\u201332.","journal-title":"J Rheumatol"},{"issue":"6","key":"555_CR20","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1093\/rheumatology\/41.6.643","volume":"41","author":"J Cort\u00e9s-Hern\u00e1ndez","year":"2002","unstructured":"Cort\u00e9s-Hern\u00e1ndez J, Ordi-Ros J, Paredes F, Casellas M, Castillo F, Vilardell-Tarres M. Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies. Rheumatology (Oxford). 2002;41(6):643\u201350.","journal-title":"Rheumatology (Oxford)"},{"key":"555_CR21","doi-asserted-by":"crossref","unstructured":"Essouma M, Nkeck JR, Motolouze K, Bigna JJ, Tchaptchet P, Nkoro GA, et al. Outcomes of pregnancy and associated factors in sub-Saharan African women with systemic lupus erythematosus: a scoping review. Lupus Sci Med. 2020;7(1):e000400.","DOI":"10.1136\/lupus-2020-000400"},{"issue":"2","key":"555_CR22","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.rdc.2007.01.002","volume":"33","author":"ME Clowse","year":"2007","unstructured":"Clowse ME. Lupus activity in pregnancy. Rheum Dis Clin North Am. 2007;33(2):237\u2013. \u2013\u200952, v.","journal-title":"Rheum Dis Clin North Am"},{"issue":"905","key":"555_CR23","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/pmj.77.905.157","volume":"77","author":"CC Mok","year":"2001","unstructured":"Mok CC, Wong RW. Pregnancy in systemic lupus erythematosus. Postgrad Med J. 2001;77(905):157\u201365.","journal-title":"Postgrad Med J"},{"issue":"4","key":"555_CR24","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.ajog.2024.03.010","volume":"231","author":"CNH Abheiden","year":"2024","unstructured":"Abheiden CNH, Blomjous BS, Slaager C, Landman A, Ket JCF, Salmon JE, et al. Systemic lupus erythematosus is associated with an increased frequency of spontaneous preterm births: systematic review and meta-analysis. Am J Obstet Gynecol. 2024;231(4):408\u2013e1621.","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"555_CR25","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12958-022-00954-x","volume":"20","author":"ZJ Li","year":"2022","unstructured":"Li ZJ, Hu HY, Ding ZL, Bian ZW, Xu YH, Wen HT, et al. Characteristics of childhood-onset systemic lupus erythematosus in pregnancy and its association with pregnancy outcomes: a retrospective comparative cohort study. Reprod Biol Endocrinol. 2022;20(1):78.","journal-title":"Reprod Biol Endocrinol"},{"issue":"5","key":"555_CR26","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1097\/BOR.0b013e328363ebf7","volume":"25","author":"M Ostensen","year":"2013","unstructured":"Ostensen M, Clowse M. Pathogenesis of pregnancy complications in systemic lupus erythematosus. Curr Opin Rheumatol. 2013;25(5):591\u20136.","journal-title":"Curr Opin Rheumatol"},{"key":"555_CR27","doi-asserted-by":"crossref","unstructured":"Conklin J, Golpanian M, Engel A, Izmirly P, Belmont HM, Dervieux T, et al. Erythrocyte complement receptor 1 (ECR1) and erythrocyte-bound C4d (EC4d) in the prediction of poor pregnancy outcomes in systemic lupus erythematosus (SLE). Lupus Sci Med. 2022;9(1):e000754.","DOI":"10.1136\/lupus-2022-000754"},{"key":"555_CR28","doi-asserted-by":"publisher","first-page":"885","DOI":"10.2147\/TCRM.S160760","volume":"14","author":"J Wu","year":"2018","unstructured":"Wu J, Ma J, Zhang WH, Di W. Management and outcomes of pregnancy with or without lupus nephritis: a systematic review and meta-analysis. Ther Clin Risk Manag. 2018;14:885\u2013901.","journal-title":"Ther Clin Risk Manag"},{"issue":"6","key":"555_CR29","first-page":"462","volume":"2","author":"G Ruiz-Irastorza","year":"2000","unstructured":"Ruiz-Irastorza G, Khamashta MA, Hughes GR. Systemic lupus erythematosus and antiphospholipid syndrome during pregnancy: maternal and fetal complications and their management. Isr Med Assoc J. 2000;2(6):462\u20139.","journal-title":"Isr Med Assoc J"},{"issue":"6","key":"555_CR30","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.5114\/ada.2022.122601","volume":"39","author":"A Liszewska","year":"2022","unstructured":"Liszewska A, Wo\u017aniacka A. Neonatal lupus erythematosus - prevention is better than cure. Postepy Dermatol Alergol. 2022;39(6):1021\u20136.","journal-title":"Postepy Dermatol Alergol"},{"issue":"3","key":"555_CR31","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.rdc.2016.03.002","volume":"42","author":"A Fayyaz","year":"2016","unstructured":"Fayyaz A, Kurien BT, Scofield RH. Autoantibodies in Sj\u00f6gren\u2019s Syndrome. Rheum Dis Clin North Am. 2016;42(3):419\u201334.","journal-title":"Rheum Dis Clin North Am"},{"issue":"1","key":"555_CR32","doi-asserted-by":"publisher","first-page":"2205513","DOI":"10.1080\/01443615.2023.2205513","volume":"43","author":"AB Sangah","year":"2023","unstructured":"Sangah AB, Jabeen S, Hunde MZ, Devi S, Mumtaz H, Shaikh SS. Maternal and fetal outcomes of SLE in pregnancy: a literature review. J Obstet Gynaecol. 2023;43(1):2205513.","journal-title":"J Obstet Gynaecol"},{"issue":"12","key":"555_CR33","doi-asserted-by":"publisher","first-page":"103467","DOI":"10.1016\/j.autrev.2023.103467","volume":"22","author":"M Radin","year":"2023","unstructured":"Radin M, Cecchi I, Crisafulli F, Klumb EM, de Jes\u00fas GR, Lacerda MI, et al. Complement levels during the first trimester predict disease flare and adverse pregnancy outcomes in systemic lupus erythematosus: A network meta-analysis on 532 pregnancies. Autoimmun Rev. 2023;22(12):103467.","journal-title":"Autoimmun Rev"},{"issue":"7","key":"555_CR34","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.3899\/jrheum.141571","volume":"42","author":"A Lea\u00f1os-Miranda","year":"2015","unstructured":"Lea\u00f1os-Miranda A, Campos-Galicia I, Berumen-Lechuga MG, Molina-P\u00e9rez CJ, Garc\u00eda-Paleta Y, Isordia-Salas I, Ram\u00edrez-Valenzuela KL. Circulating Angiogenic Factors and the Risk of Preeclampsia in Systemic Lupus Erythematosus Pregnancies. J Rheumatol. 2015;42(7):1141\u20139.","journal-title":"J Rheumatol"},{"issue":"1","key":"555_CR35","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ajog.2015.09.066","volume":"214","author":"MY Kim","year":"2016","unstructured":"Kim MY, Buyon JP, Guerra MM, Rana S, Zhang D, Laskin CA, et al. Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. Am J Obstet Gynecol. 2016;214(1):108.e1-.e14.","journal-title":"Am J Obstet Gynecol"},{"key":"555_CR36","doi-asserted-by":"crossref","unstructured":"Fazzari MJ, Guerra MM, Salmon J, Kim MY. Adverse pregnancy outcomes in women with systemic lupus erythematosus: can we improve predictions with machine learning? Lupus Sci Med. 2022;9(1):e000769.","DOI":"10.1136\/lupus-2022-000769"},{"issue":"6","key":"555_CR37","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/anr.1780320602","volume":"32","author":"MD Lockshin","year":"1989","unstructured":"Lockshin MD. Pregnancy does not cause systemic lupus erythematosus to worsen. Arthritis Rheum. 1989;32(6):665\u201370.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"555_CR38","first-page":"252","volume":"14","author":"RT Meehan","year":"1987","unstructured":"Meehan RT, Dorsey JK. Pregnancy among patients with systemic lupus erythematosus receiving immunosuppressive therapy. J Rheumatol. 1987;14(2):252\u20138.","journal-title":"J Rheumatol"},{"issue":"3","key":"555_CR39","doi-asserted-by":"publisher","first-page":"153","DOI":"10.7326\/M14-2235","volume":"163","author":"JP Buyon","year":"2015","unstructured":"Buyon JP, Kim MY, Guerra MM, Laskin CA, Petri M, Lockshin MD, et al. Predictors of Pregnancy Outcomes in Patients With Lupus: A Cohort Study. Ann Intern Med. 2015;163(3):153\u201363.","journal-title":"Ann Intern Med"},{"issue":"12","key":"555_CR40","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1002\/art.1780341210","volume":"34","author":"M Petri","year":"1991","unstructured":"Petri M, Howard D, Repke J. Frequency of lupus flare in pregnancy. The Hopkins Lupus Pregnancy Center experience. Arthritis Rheum. 1991;34(12):1538\u201345.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"555_CR41","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1136\/annrheumdis-2013-204620","volume":"74","author":"MF Ugarte-Gil","year":"2015","unstructured":"Ugarte-Gil MF, Acevedo-V\u00e1squez E, Alarc\u00f3n GS, Pastor-Asurza CA, Alfaro-Lozano JL, Cucho-Venegas JM, et al. The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort. Ann Rheum Dis. 2015;74(6):1019\u201323.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"555_CR42","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s10067-013-2180-z","volume":"32","author":"C Zhao","year":"2013","unstructured":"Zhao C, Zhao J, Huang Y, Wang Z, Wang H, Zhang H, et al. New-onset systemic lupus erythematosus during pregnancy. Clin Rheumatol. 2013;32(6):815\u201322.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"555_CR43","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13075-024-03298-6","volume":"26","author":"T Nakai","year":"2024","unstructured":"Nakai T, Honda N, Soga E, Fukui S, Kitada A, Yokogawa N, Okada M. Effect of remission, clinical remission with active serology, and glucocorticoid dosage on the pregnancy outcome of pregnant patients with systemic lupus erythematosus. Arthritis Res Ther. 2024;26(1):63.","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"555_CR44","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1177\/0961203310371154","volume":"19","author":"DJ Birmingham","year":"2010","unstructured":"Birmingham DJ, Irshaid F, Nagaraja HN, Zou X, Tsao BP, Wu H, et al. The complex nature of serum C3 and C4 as biomarkers of lupus renal flare. Lupus. 2010;19(11):1272\u201380.","journal-title":"Lupus"},{"issue":"3","key":"555_CR45","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.cellsig.2013.11.002","volume":"26","author":"Q Huang","year":"2014","unstructured":"Huang Q, Chen H, Li J, Oliver M, Ma X, Byck D, et al. Epigenetic and non-epigenetic regulation of syncytin-1 expression in human placenta and cancer tissues. Cell Signal. 2014;26(3):648\u201356.","journal-title":"Cell Signal"},{"issue":"1","key":"555_CR46","first-page":"185","volume":"102","author":"AG Lokossou","year":"2020","unstructured":"Lokossou AG, Toudic C, Nguyen PT, Elisseeff X, Vargas A, Rassart \u00c9, et al. Endogenous retrovirus-encoded Syncytin-2 contributes to exosome-mediated immunosuppression of T cells\u2020. Biol Reprod. 2020;102(1):185\u201398.","journal-title":"Biol Reprod"},{"key":"555_CR47","doi-asserted-by":"crossref","unstructured":"Talotta R. Interaction between long noncoding RNAs and Syncytin-1\/Syncytin-2 genes and transcripts: how noncoding RNAs may affect pregnancy in patients with systemic lupus erythematosus. Int J Mol Sci. 2023;24(3):2259.","DOI":"10.3390\/ijms24032259"},{"issue":"1","key":"555_CR48","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S0002-9378(98)70277-7","volume":"179","author":"MS Magid","year":"1998","unstructured":"Magid MS, Kaplan C, Sammaritano LR, Peterson M, Druzin ML, Lockshin MD. Placental pathology in systemic lupus erythematosus: a prospective study. Am J Obstet Gynecol. 1998;179(1):226\u201334.","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"555_CR49","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1210\/en.2012-1927","volume":"154","author":"JL Nugent","year":"2013","unstructured":"Nugent JL, Wareing M, Palin V, Sibley CP, Baker PN, Ray DW, et al. Chronic glucocorticoid exposure potentiates placental chorionic plate artery constriction: implications for aberrant fetoplacental vascular resistance in fetal growth restriction. Endocrinology. 2013;154(2):876\u201387.","journal-title":"Endocrinology"},{"issue":"9","key":"555_CR50","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1084\/jem.20061022","volume":"203","author":"G Girardi","year":"2006","unstructured":"Girardi G, Yarilin D, Thurman JM, Holers VM, Salmon JE. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med. 2006;203(9):2165\u201375.","journal-title":"J Exp Med"},{"issue":"10","key":"555_CR51","doi-asserted-by":"publisher","first-page":"R381","DOI":"10.1016\/S0960-9822(00)00476-0","volume":"10","author":"BP Morgan","year":"2000","unstructured":"Morgan BP, Holmes CH. Immunology of reproduction: protecting the placenta. Curr Biol. 2000;10(10):R381\u20133.","journal-title":"Curr Biol"},{"issue":"4","key":"555_CR52","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1136\/annrheumdis-2017-212224","volume":"77","author":"MY Kim","year":"2018","unstructured":"Kim MY, Guerra MM, Kaplowitz E, Laskin CA, Petri M, Branch DW, et al. Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and\/or antiphospholipid antibodies. Ann Rheum Dis. 2018;77(4):549\u201355.","journal-title":"Ann Rheum Dis"},{"key":"555_CR53","doi-asserted-by":"publisher","first-page":"449","DOI":"10.3389\/fimmu.2019.00449","volume":"10","author":"S Chaturvedi","year":"2019","unstructured":"Chaturvedi S, Brodsky RA, McCrae KR. Complement in the Pathophysiology of the Antiphospholipid Syndrome. Front Immunol. 2019;10:449.","journal-title":"Front Immunol"},{"issue":"3","key":"555_CR54","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1136\/annrheumdis-2016-209770","volume":"76","author":"L Andreoli","year":"2017","unstructured":"Andreoli L, Bertsias GK, Agmon-Levin N, Brown S, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for women\u2019s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and\/or antiphospholipid syndrome. Ann Rheum Dis. 2017;76(3):476\u201385.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"555_CR55","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.ard.2025.02.023","volume":"84","author":"L R\u00fcegg","year":"2025","unstructured":"R\u00fcegg L, Pluma A, Hamroun S, Cecchi I, Perez-Garcia LF, Anderson PO, et al. EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update. Ann Rheum Dis. 2025;84(6):910\u201326.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"555_CR56","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1093\/rheumatology\/34.5.435","volume":"34","author":"CJ Laversuch","year":"1995","unstructured":"Laversuch CJ, Collins DA, Charles PJ, Bourke BE. Sulphasalazine-induced autoimmune abnormalities in patients with rheumatic disease. Br J Rheumatol. 1995;34(5):435\u20139.","journal-title":"Br J Rheumatol"},{"key":"555_CR57","doi-asserted-by":"crossref","unstructured":"Saegusa K, Tsuchida Y, Komai T, Tsuchiya H, Fujio K. Advances in targeted therapy for systemic lupus erythematosus: current treatments and novel approaches. Int J Mol Sci. 2025;26(3):929.","DOI":"10.3390\/ijms26030929"},{"issue":"3","key":"555_CR58","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1136\/ard.45.3.244","volume":"45","author":"Y Miyachi","year":"1986","unstructured":"Miyachi Y, Yoshioka A, Imamura S, Niwa Y. Antioxidant action of antimalarials. Ann Rheum Dis. 1986;45(3):244\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"555_CR59","doi-asserted-by":"publisher","first-page":"e12476","DOI":"10.15252\/emmm.202012476","volume":"12","author":"EL Nirk","year":"2020","unstructured":"Nirk EL, Reggiori F, Mauthe M. Hydroxychloroquine in rheumatic autoimmune disorders and beyond. EMBO Mol Med. 2020;12(8):e12476.","journal-title":"EMBO Mol Med"},{"issue":"11","key":"555_CR60","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1002\/art.11304","volume":"48","author":"N Costedoat-Chalumeau","year":"2003","unstructured":"Costedoat-Chalumeau N, Amoura Z, Duhaut P, Huong DL, Sebbough D, Wechsler B, et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum. 2003;48(11):3207\u201311.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"555_CR61","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1093\/rheumatology\/keac372","volume":"62","author":"JA Reynolds","year":"2023","unstructured":"Reynolds JA, Gayed M, Khamashta MA, Leone F, Toescu V, Bruce IN, et al. Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprine. Rheumatology (Oxford). 2023;62(3):1124\u201335.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"555_CR62","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/j.1708-8305.1998.tb00484.x","volume":"5","author":"PA Phillips-Howard","year":"1998","unstructured":"Phillips-Howard PA, Steffen R, Kerr L, Vanhauwere B, Schildknecht J, Fuchs E, Edwards R. Safety of mefloquine and other antimalarial agents in the first trimester of pregnancy. J Travel Med. 1998;5(3):121\u20136.","journal-title":"J Travel Med"},{"key":"555_CR63","first-page":"6","volume":"7","author":"W Ebel","year":"2007","unstructured":"Ebel W, Routhier EL, Foley B, Jacob S, McDonough JM, Patel RK, et al. Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun. 2007;7:6.","journal-title":"Cancer Immun"},{"issue":"5","key":"555_CR64","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s10067-022-06496-2","volume":"42","author":"Y Liu","year":"2023","unstructured":"Liu Y, Wei Y, Zhang Y, Yang H. Hydroxychloroquine significantly decreases the risk of preeclampsia in pregnant women with autoimmune disorders: a systematic review and meta-analysis. Clin Rheumatol. 2023;42(5):1223\u201335.","journal-title":"Clin Rheumatol"},{"issue":"10","key":"555_CR65","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1136\/ard.2009.119263","volume":"69","author":"PM Izmirly","year":"2010","unstructured":"Izmirly PM, Kim MY, Llanos C, Le PU, Guerra MM, Askanase AD, et al. Evaluation of the risk of anti-SSA\/Ro-SSB\/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Ann Rheum Dis. 2010;69(10):1827\u201330.","journal-title":"Ann Rheum Dis"},{"issue":"suppl5","key":"555_CR66","doi-asserted-by":"publisher","first-page":"v9","DOI":"10.1093\/rheumatology\/key141","volume":"57","author":"MEB Clowse","year":"2018","unstructured":"Clowse MEB, Eudy AM, Kiernan E, Williams MR, Bermas B, Chakravarty E, et al. The prevention, screening and treatment of congenital heart block from neonatal lupus: a survey of provider practices. Rheumatology (Oxford). 2018;57(suppl5):v9\u201317.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"555_CR67","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1056\/NEJM199101173240303","volume":"324","author":"Canadian Hydroxychloroquine Study Group","year":"1991","unstructured":"Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med. 1991;324(3):150\u20134.","journal-title":"N Engl J Med"},{"issue":"6","key":"555_CR68","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1191\/0961203306lu2313oa","volume":"15","author":"N Kasitanon","year":"2006","unstructured":"Kasitanon N, Fine DM, Haas M, Magder LS, Petri M. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus. 2006;15(6):366\u201370.","journal-title":"Lupus"},{"issue":"1","key":"555_CR69","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/bcp.14131","volume":"86","author":"C de Moreuil","year":"2020","unstructured":"de Moreuil C, Alavi Z, Pasquier E. Hydroxychloroquine may be beneficial in preeclampsia and recurrent miscarriage. Br J Clin Pharmacol. 2020;86(1):39\u201349.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"555_CR70","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1080\/14740338.2017.1269168","volume":"16","author":"C Ponticelli","year":"2017","unstructured":"Ponticelli C, Moroni G. Hydroxychloroquine in systemic lupus erythematosus (SLE). Expert Opin Drug Saf. 2017;16(3):411\u20139.","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"555_CR71","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/1529-0131(200104)45:2<191::AID-ANR173>3.0.CO;2-2","volume":"45","author":"GS Alarc\u00f3n","year":"2001","unstructured":"Alarc\u00f3n GS, McGwin G Jr., Bastian HM, Roseman J, Lisse J, Fessler BJ, et al. Systemic lupus erythematosus in three ethnic groups. VII [correction of VIII]. Predictors of early mortality in the LUMINA cohort. LUMINA Study Group. Arthritis Rheum. 2001;45(2):191\u2013202.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"555_CR72","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40268-022-00408-0","volume":"23","author":"N Zhang","year":"2023","unstructured":"Zhang N, Zhang HX, Li YW, Li Y. Benefits of Hydroxychloroquine Combined with Low-Dose Aspirin on Pregnancy Outcomes and Serum Cytokines in Pregnant Women with Systemic Lupus Erythematosus. Drugs R D. 2023;23(1):35\u201342.","journal-title":"Drugs R D"},{"issue":"6","key":"555_CR73","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nrrheum.2010.60","volume":"6","author":"JC Crisp\u00edn","year":"2010","unstructured":"Crisp\u00edn JC, Kyttaris VC, Terhorst C, Tsokos GC. T cells as therapeutic targets in SLE. Nat Rev Rheumatol. 2010;6(6):317\u201325.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"555_CR74","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13075-023-03256-8","volume":"26","author":"T Nakai","year":"2024","unstructured":"Nakai T, Honda N, Soga E, Fukui S, Kitada A, Yokogawa N, Okada M. A retrospective analysis of the safety of tacrolimus use and its optimal cut-off concentration during pregnancy in women with systemic lupus erythematosus: study from two Japanese tertiary referral centers. Arthritis Res Ther. 2024;26(1):15.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"555_CR75","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1111\/bcp.12122","volume":"76","author":"S Zheng","year":"2013","unstructured":"Zheng S, Easterling TR, Hays K, Umans JG, Miodovnik M, Clark S, et al. Tacrolimus placental transfer at delivery and neonatal exposure through breast milk. Br J Clin Pharmacol. 2013;76(6):988\u201396.","journal-title":"Br J Clin Pharmacol"},{"key":"555_CR76","doi-asserted-by":"publisher","first-page":"27915","DOI":"10.1038\/srep27915","volume":"6","author":"R Rodrigues-Diez","year":"2016","unstructured":"Rodrigues-Diez R, Gonz\u00e1lez-Guerrero C, Oca\u00f1a-Salceda C, Rodrigues-Diez RR, Egido J, Ortiz A, et al. Calcineurin inhibitors cyclosporine A and tacrolimus induce vascular inflammation and endothelial activation through TLR4 signaling. Sci Rep. 2016;6:27915.","journal-title":"Sci Rep"},{"issue":"16","key":"555_CR77","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/j.jacc.2018.12.092","volume":"73","author":"AD Lane-Cordova","year":"2019","unstructured":"Lane-Cordova AD, Khan SS, Grobman WA, Greenland P, Shah SJ. Long-Term Cardiovascular Risks Associated With Adverse Pregnancy Outcomes: JACC Review Topic of the Week. J Am Coll Cardiol. 2019;73(16):2106\u201316.","journal-title":"J Am Coll Cardiol"},{"key":"555_CR78","doi-asserted-by":"crossref","unstructured":"Haga K, Shibuya T, Nomura K, Okahara K, Nomura O, Ishikawa D, et al. Effectiveness and nephrotoxicity of long-term tacrolimus administration in patients with ulcerative colitis. J Clin Med. 2020;9(6):1771.","DOI":"10.3390\/jcm9061771"},{"issue":"11","key":"555_CR79","doi-asserted-by":"publisher","first-page":"e0143405","DOI":"10.1371\/journal.pone.0143405","volume":"10","author":"Z Li","year":"2015","unstructured":"Li Z, Sun F, Zhang Y, Chen H, He N, Chen H, et al. Tacrolimus Induces Insulin Resistance and Increases the Glucose Absorption in the Jejunum: A Potential Mechanism of the Diabetogenic Effects. PLoS ONE. 2015;10(11):e0143405.","journal-title":"PLoS ONE"},{"issue":"3","key":"555_CR80","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1177\/09612033221148334","volume":"32","author":"A Kitada","year":"2023","unstructured":"Kitada A, Nakai T, Fukui S, Rokutanda R, Okada M, Kusaoi M, et al. Safety of tacrolimus use during pregnancy and related pregnancy outcomes in patients with systemic lupus erythematosus: A retrospective single-center analysis in Japan. Lupus. 2023;32(3):352\u201362.","journal-title":"Lupus"},{"issue":"6","key":"555_CR81","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/aji.12514","volume":"75","author":"R Reggia","year":"2016","unstructured":"Reggia R, Bazzani C, Andreoli L, Motta M, Lojacono A, Zatti S, et al. The Efficacy and Safety of Cyclosporin A in Pregnant Patients with Systemic Autoimmune Diseases. Am J Reprod Immunol. 2016;75(6):654\u201360.","journal-title":"Am J Reprod Immunol"},{"issue":"5","key":"555_CR82","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1586\/1744666X.2015.1033404","volume":"11","author":"C Ponticelli","year":"2015","unstructured":"Ponticelli C, Moroni G. Immunosuppression in pregnant women with systemic lupus erythematosus. Expert Rev Clin Immunol. 2015;11(5):549\u201352.","journal-title":"Expert Rev Clin Immunol"},{"issue":"8","key":"555_CR83","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/0002-9378(73)90559-0","volume":"115","author":"S Saarikoski","year":"1973","unstructured":"Saarikoski S, Sepp\u00e4l\u00e4 M. Immunosuppression during pregnancy: transmission of azathioprine and its metabolites from the mother to the fetus. Am J Obstet Gynecol. 1973;115(8):1100\u20136.","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"555_CR84","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1177\/096120339600500205","volume":"5","author":"JO Mart\u00ednez-Rueda","year":"1996","unstructured":"Mart\u00ednez-Rueda JO, Arce-Salinas CA, Kraus A, Alcocer-Varela J, Alarc\u00f3n-Segovia D. Factors associated with fetal losses in severe systemic lupus erythematosus. Lupus. 1996;5(2):113\u20139.","journal-title":"Lupus"},{"issue":"2","key":"555_CR85","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1093\/rheumatology\/kex353","volume":"57","author":"PL Indraratna","year":"2018","unstructured":"Indraratna PL, Virk S, Gurram D, Day RO. Use of colchicine in pregnancy: a systematic review and meta-analysis. Rheumatology (Oxford). 2018;57(2):382\u20137.","journal-title":"Rheumatology (Oxford)"},{"key":"555_CR86","doi-asserted-by":"crossref","unstructured":"Dawi J, Affa S, Misakyan Y, Fardeheb S, Kades S, Kiriaki A, et al. Exploring cardiovascular implications in systemic lupus erythematosus: a holistic analysis of complications, diagnostic criteria, and therapeutic modalities, encompassing pharmacological and adjuvant approaches. Biomol Concepts. 2024;15(1):10.","DOI":"10.1515\/bmc-2022-0051"},{"issue":"1","key":"555_CR87","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.cgh.2020.09.021","volume":"20","author":"OH Nielsen","year":"2022","unstructured":"Nielsen OH, Gubatan JM, Juhl CB, Streett SE, Maxwell C. Biologics for Inflammatory Bowel Disease and Their Safety in Pregnancy: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2022;20(1):74\u2013e873.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"555_CR88","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1111\/1471-0528.17093","volume":"129","author":"LJ O\u2019Byrne","year":"2022","unstructured":"O\u2019Byrne LJ, Alqatari SG, Maher GM, O\u2019Sullivan AM, Khashan AS, Murphy GP, McCarthy FP. Fetal and maternal outcomes after maternal biologic use during conception and pregnancy: A systematic review and meta-analysis. BJOG. 2022;129(8):1236\u201346.","journal-title":"BJOG"},{"issue":"6","key":"555_CR89","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.semarthrit.2021.09.004","volume":"51","author":"H Nguyen","year":"2021","unstructured":"Nguyen H, Ahmed K, Luo W, Flint J, Giles I. A Systematic Review of the safety of non-TNF inhibitor biologic and targeted synthetic drugs in rheumatic disease in pregnancy. Semin Arthritis Rheum. 2021;51(6):1205\u201317.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"555_CR90","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/bdr2.2091","volume":"115","author":"P Juliao","year":"2023","unstructured":"Juliao P, Wurst K, Pimenta JM, Gemzoe K, Landy H, Moody MA, et al. Belimumab use during pregnancy: Interim results of the belimumab pregnancy registry. Birth Defects Res. 2023;115(2):188\u2013204.","journal-title":"Birth Defects Res"},{"issue":"1","key":"555_CR91","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1177\/09612033221141805","volume":"32","author":"Y Lai","year":"2023","unstructured":"Lai Y, Li B, Huang J, Du J, Yue M, Shen X, et al. Different pregnancy outcomes in patients with systemic lupus erythematosus treated with belimumab. Lupus. 2023;32(1):149\u201354.","journal-title":"Lupus"},{"issue":"5","key":"555_CR92","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.semarthrit.2021.06.005","volume":"51","author":"JH Kao","year":"2021","unstructured":"Kao JH, Lan TY, Lu CH, Cheng CF, Huang YM, Shen CY, Hsieh SC. Pregnancy outcomes in patients treated with belimumab: Report from real-world experience. Semin Arthritis Rheum. 2021;51(5):963\u20138.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"555_CR93","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2024","unstructured":"Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83(1):15\u201329.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"555_CR94","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1002\/bdra.10134","volume":"67","author":"P Pradat","year":"2003","unstructured":"Pradat P, Robert-Gnansia E, Di Tanna GL, Rosano A, Lisi A, Mastroiacovo P. First trimester exposure to corticosteroids and oral clefts. Birth Defects Res Clin Mol Teratol. 2003;67(12):968\u201370.","journal-title":"Birth Defects Res Clin Mol Teratol"},{"issue":"10","key":"555_CR95","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1136\/ard.62.10.1010","volume":"62","author":"N Costedoat-Chalumeau","year":"2003","unstructured":"Costedoat-Chalumeau N, Amoura Z, Le Thi Hong D, Wechsler B, Vauthier D, Ghillani P, et al. Questions about dexamethasone use for the prevention of anti-SSA related congenital heart block. Ann Rheum Dis. 2003;62(10):1010\u20132.","journal-title":"Ann Rheum Dis"},{"issue":"5 Pt 2","key":"555_CR96","first-page":"810","volume":"96","author":"RP Holmes","year":"2000","unstructured":"Holmes RP, Stone PR. Severe oligohydramnios induced by cyclooxygenase-2 inhibitor nimesulide. Obstet Gynecol. 2000;96(5 Pt 2):810\u20131.","journal-title":"Obstet Gynecol"},{"issue":"1","key":"555_CR97","first-page":"70","volume":"31","author":"S Topuz","year":"2004","unstructured":"Topuz S, Has R, Ermi\u015f H, Yildirim A, Ibrahimo\u011flu L, Y\u00fcksel A. Acute severe reversible oligohydramnios induced by indomethacin in a patient with rheumatoid arthritis: a case report and review of the literature. Clin Exp Obstet Gynecol. 2004;31(1):70\u20132.","journal-title":"Clin Exp Obstet Gynecol"},{"issue":"7411","key":"555_CR98","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1136\/bmj.327.7411.368","volume":"327","author":"DK Li","year":"2003","unstructured":"Li DK, Liu L, Odouli R. Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study. BMJ. 2003;327(7411):368.","journal-title":"BMJ"},{"issue":"3","key":"555_CR99","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/ar1957","volume":"8","author":"M \u00d8stensen","year":"2006","unstructured":"\u00d8stensen M, Khamashta M, Lockshin M, Parke A, Brucato A, Carp H, et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther. 2006;8(3):209.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"555_CR100","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1542\/peds.107.3.519","volume":"107","author":"MA Alano","year":"2001","unstructured":"Alano MA, Ngougmna E, Ostrea EM Jr., Konduri GG. Analysis of nonsteroidal antiinflammatory drugs in meconium and its relation to persistent pulmonary hypertension of the newborn. Pediatrics. 2001;107(3):519\u201323.","journal-title":"Pediatrics"},{"issue":"7930","key":"555_CR101","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/S0140-6736(75)92778-6","volume":"2","author":"G Turner","year":"1975","unstructured":"Turner G, Collins E. Fetal effects of regular salicylate ingestion in pregnancy. Lancet. 1975;2(7930):338\u20139.","journal-title":"Lancet"},{"issue":"16","key":"555_CR102","doi-asserted-by":"publisher","first-page":"e86","DOI":"10.1097\/MD.0000000000000086","volume":"93","author":"R Sakthiswary","year":"2014","unstructured":"Sakthiswary R, D\u2019Cruz D. Intravenous immunoglobulin in the therapeutic armamentarium of systemic lupus erythematosus: a systematic review and meta-analysis. Med (Baltim). 2014;93(16):e86.","journal-title":"Med (Baltim)"},{"issue":"11","key":"555_CR103","doi-asserted-by":"publisher","first-page":"103182","DOI":"10.1016\/j.autrev.2022.103182","volume":"21","author":"J Cajamarca-Bar\u00f3n","year":"2022","unstructured":"Cajamarca-Bar\u00f3n J, Buitrago-Boh\u00f3rquez J, Mendoza Orozco JE, Segura O, Guavita-Navarro D, Gallego-Cardona L, et al. Efficacy and safety of intravenous immunoglobulin in patients with lupus nephritis: A systematic review of the literature. Autoimmun Rev. 2022;21(11):103182.","journal-title":"Autoimmun Rev"},{"issue":"7","key":"555_CR104","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1191\/096120398678920451","volume":"7","author":"C Gordon","year":"1998","unstructured":"Gordon C, Kilby MD. Use of intravenous immunoglobulin therapy in pregnancy in systemic lupus erythematosus and antiphospholipid antibody syndrome. Lupus. 1998;7(7):429\u201333.","journal-title":"Lupus"},{"key":"555_CR105","unstructured":"Clowse M, Isenberg D, Merrill J, Dorner T, Petri M, Vital E, et al. Dapirolizumab pegol demonstrated significant improvement in systemic lupus erythematosus disease activity: efficacy and safety results of a Phase 3 trial [abstract]. ACR Convergence 2024 [Internet]. 2024. Available from: https:\/\/acrabstracts.org\/abstract\/dapirolizumab-pegol-demonstrated-significant-improvement-in-systemic-lupus-erythematosus-disease-activity-efficacy-and-safety-results-of-a-phase-3-trial\/. Accessed June 4, 2025."},{"issue":"11","key":"555_CR106","doi-asserted-by":"publisher","first-page":"5397","DOI":"10.1093\/rheumatology\/keab381","volume":"60","author":"RA Furie","year":"2021","unstructured":"Furie RA, Bruce IN, D\u00f6rner T, Leon MG, Leszczy\u0144ski P, Urowitz M, et al. Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. Rheumatology (Oxford). 2021;60(11):5397\u2013407.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"555_CR107","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","volume":"20","author":"G Schett","year":"2024","unstructured":"Schett G, M\u00fcller F, Taubmann J, Mackensen A, Wang W, Furie RA, et al. Advancements and challenges in CAR T cell therapy in autoimmune diseases. Nat Rev Rheumatol. 2024;20(9):531\u201344.","journal-title":"Nat Rev Rheumatol"},{"key":"555_CR108","doi-asserted-by":"crossref","unstructured":"Canty EA, Broderick L, Flaherty D, Xavier M, Nasta SD, Dajani L, White AA. First reported case of a spontaneous and healthy pregnancy in a woman with persistent CAR T-cells 5 years after treatment for diffuse large B-cell lymphoma. J Immunother Cancer. 2025;13(4):e011092.","DOI":"10.1136\/jitc-2024-011092"},{"issue":"2","key":"555_CR109","first-page":"146","volume":"122","author":"D O\u2019Reilly","year":"2025","unstructured":"O\u2019Reilly D, Jones C, Smith A, Mackin D, Mc Donald L, Quinn J, et al. Neonatal Outcomes following 2 Cases of Maternal CAR-T Therapy for High-Grade B-Cell Lymphoma. Neonatology. 2025;122(2):146\u201350.","journal-title":"Neonatology"},{"issue":"6","key":"555_CR110","first-page":"1119","volume":"56","author":"M Wang","year":"2024","unstructured":"Wang M, Ding L, Wang M, Zou C, Yan S, Liang Y, et al. [Safe pregnancy and delivery in a female patient with systemic lupus erythematosus after discontinuation of dual-target chimeric antigen receptor T cells therapy]. Beijing Da Xue Xue Bao Yi Xue Ban. 2024;56(6):1119\u201325.","journal-title":"Beijing Da Xue Xue Bao Yi Xue Ban"},{"key":"555_CR111","doi-asserted-by":"crossref","unstructured":"Moroni G, Calatroni M, Donato B, Ponticelli C. Kidney biopsy in pregnant women with glomerular diseases: focus on lupus nephritis. J Clin Med. 2023;12(5):1834.","DOI":"10.3390\/jcm12051834"}],"container-title":["Advances in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42358-026-00555-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-026-00555-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-026-00555-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T02:02:23Z","timestamp":1787277743000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s42358-026-00555-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":111,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["555"],"URL":"https:\/\/doi.org\/10.1186\/s42358-026-00555-x","relation":{},"ISSN":["2523-3106"],"issn-type":[{"value":"2523-3106","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"18 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None.","order":1,"name":"Ethics","label":"Disclosures","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"48"}}